Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12882
Abstract: The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed… read more here.
Keywords: cardiovascular adverse; myeloma; treatment; myeloma patients ... See more keywords